Last ¥1,109 JPY
Change Today -30.00 / -2.63%
Volume 5.8M
4503 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
Frankfurt
As of 2:00 AM 04/21/14 All times are local (Market data is delayed by at least 15 minutes).

astellas pharma inc (4503) Snapshot

Open
¥1,139
Previous Close
¥1,139
Day High
¥1,142
Day Low
¥1,108
52 Week High
02/28/14 - ¥1,340
52 Week Low
06/13/13 - ¥935.00
Market Cap
2.5T
Average Volume 10 Days
8.5M
EPS TTM
¥35.81
Shares Outstanding
2.3B
EX-Date
03/27/14
P/E TM
31.0x
Dividend
¥27.00
Dividend Yield
2.43%
Current Stock Chart for ASTELLAS PHARMA INC (4503)

Related News

No related news articles were found.

astellas pharma inc (4503) Related Businessweek News

View More BusinessWeek News

astellas pharma inc (4503) Details

Astellas Pharma Inc. manufactures, markets, and imports/exports pharmaceutical products worldwide. The company focuses on therapeutic areas of urology, immunology and infectious diseases, oncology, neuroscience, and diabetes mellitus complications and kidney diseases. Its products include Prograf, an immunosuppressant to prevent rejection in organ transplants; Protopic for the treatment of atopic dermatitis in the topical immunomodulator class; Vesicare, a treatment for overactive bladder; Harnal, an a1 blocking agent for the treatment of benign prostatic hyperplasia; and Funguard, a candin antifungal agent. The company’s products also comprise Geninax, an oral quinolone antibacterial agent; Celecox, a selective COX-2 inhibitor; Lipitor, a treatment for hypercholesterolemia; Micardis, a treatment hypertension; Gaster, a treatment for peptic ulcers and gastritis; Myslee, a hypnotic; Cefzon, an oral cephalosporin; Seroquel, an antipsychotic agent; Dorner, a treatment for chronic arterial occlusion; Nasea, an antagonist; Regnite, a treatment for restless legs syndrome; and Kiklin, a treatment for hyperphatemia. In addition, it offers Lexiscan and Adenoscan, which are pharmacologic stress agents; Tarceva, a treatment for non-small cell lung cancer; Vaprisol, a treatment for euvolemic hyponatremia; AmBisome, a systemic antifungal agent; Eligard, a treatment for advanced prostate cancer; Locoid, a topical corticosteroid; Zineryt, a treatment for acne; Locobase, a treatment for dry skin; and Dificlir, a novel treatment for CDI. It has a strategic alliance with Amgen Inc.; a collaborative research agreement with Immuno-Biological Laboratories Co., Ltd.; a compound library sharing partnership with Daiichi Sankyo Company, Limited; and a strategic partnership with ClearPath Development Company. The company was founded in 1923 and is headquartered in Tokyo, Japan.

17,454 Employees
Last Reported Date: 09/28/13
Founded in 1923

astellas pharma inc (4503) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

astellas pharma inc (4503) Key Developments

Astellas Pharma, Inc. and MSD K.K. Announce Availability of Diabetes Drug in Japan

Astellas Pharma, Inc. and MSD K.K. have announced the availability of Suglat tablets 25mg and 50mg for the indication of type 2 diabetes in Japan. Suglat Tablets is a selective SGLT2 (Sodium-Glucose Co-Transporter 2) inhibitor discovered through a research collaboration and is being jointly developed by Astellas and Kotobuki Pharmaceutical Co. Ltd. SGLTs are membrane proteins that exist on the cell surface and transfer glucose into cells. SGLT2 is one subtype of SGLTs and plays a key role in the reuptake of glucose in the proximal tubule of the kidneys. Suglat Tablets reduces blood glucose levels by inhibiting the reuptake of glucose by selectively inhibiting SGLT2. Suglat Tablets is the first SGLT2 inhibitor approved as a treatment for type 2 diabetes in Japan. Astellas will manufacture and sell Suglat Tablets and co-promote it with Kotobuki and MSD.

Astellas Pharma Inc. and Medivation Inc. Announce European Regulatory Submission for XTANDI (Enzalutamide) Capsules for Chemotherapy-Naive Metastatic Prostate Cancer

Astellas Pharma Inc. and Medivation Inc. announced the submission of a variation to amend the European Marketing Authorization Application for XTANDI (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated. XTANDI is currently approved in Europe for the treatment of adult men with mCRPC whose disease has progressed on or after docetaxel chemotherapy. The European application is based on the results from the Phase 3 PREVAIL trial evaluating XTANDI as compared to placebo in more than 1,700 chemotherapy-naive mCRPC patients.

Astellas Pharma Establishes Regenerative Medicine Unit

Astellas Pharma Inc. has established a regenerative medicine unit as an organization reporting to the senior vice president and president of drug discovery research. The company announced in May last year that it would expand the effort in the regenerative medicine and would make full-fledged effort in the cell therapy in addition to the discovery R&D of conventional pharmaceuticals for regenerative medicine that it had been working on. Now the company has established a new organization that will specialize in the research of the regenerative medicine and cell therapy to accelerate the advancement to the emerging medical field with cutting-edge technology platform. The Regenerative Medicine Unit will implement the following activities in order to continuously create pipelines for regenerative medicine and cell therapy that will have advantages in the competition, in a speedy manner. To establish and maintain technology platform involving regenerative medicine and cell therapy taking advantage of multi-functional characteristics of cells in order to realize higher efficacy of treatment that cannot be achieved by existing therapy. To bear the hub function as the core research unit of regenerative medicine and cell therapy research.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4503:JP ¥1,109.00 JPY -30.00

4503 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $197.39 USD -1.99
Becton Dickinson and Co $113.16 USD +0.23
Mylan Inc/PA $46.92 USD -0.29
Shire PLC 2,925 GBp +25.00
Solvay SA €112.75 EUR +0.50
View Industry Companies
 

Industry Analysis

4503

Industry Average

Valuation 4503 Industry Range
Price/Earnings 33.2x
Price/Sales 2.3x
Price/Book 2.3x
Price/Cash Flow 33.6x
TEV/Sales 2.0x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTELLAS PHARMA INC, please visit www.astellas.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.